Lilly Asia Ventures took part in a series B-plus round that marks the first for biopharmaceutical company Transcenta Holding, formed through the merger of two of the corporate's portfolio companies.

China-based biopharmaceuticals developer Transcenta Holding has received $100m in a series B-plus round featuring Lilly Asia Ventures, the Asia-focused corporate venturing vehicle for pharmaceutical firm Eli Lilly. The round was co-led by CR-CP Life Science Fund and Fortune Capital, while Temasek, Epiphron Capital, CCT China Merchant Buyout Fund, China Equity Group, Hillhouse Capital, Teng Yue…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.